当前位置:首页 - 行情中心 - 赛托生物(300583) - 财务分析 - 利润表

赛托生物

(300583)

  

流通市值:27.90亿  总市值:28.51亿
流通股本:1.86亿   总股本:1.90亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入923,225,289.28663,655,673.27334,785,915.821,312,111,843.45
营业收入923,225,289.28663,655,673.27334,785,915.821,312,111,843.45
二、营业总成本877,557,142.67612,618,989.7313,685,870.451,267,351,438.89
营业成本684,779,546483,644,813.41245,803,460.081,039,302,097.06
税金及附加9,682,676.116,655,960.363,413,508.912,079,535.92
销售费用11,715,316.938,197,419.783,862,099.9514,613,447.06
管理费用104,486,456.1369,397,336.5436,344,033.29116,042,839.41
研发费用41,727,262.0727,913,511.7113,999,442.8150,205,293.08
财务费用25,165,885.4316,809,947.910,263,325.4235,108,226.36
其中:利息费用26,654,991.1617,639,329.5311,326,281.0236,886,031.56
其中:利息收入3,818,006.022,511,430.611,143,237.383,712,403.08
加:投资收益3,448,768.161,845,404.081,221,085.937,995,928.53
资产处置收益165,229.15165,229.15--107,850.48
资产减值损失(新)-1,752,604.51-6,536,339.92-486,488.31-6,885,720.98
信用减值损失(新)-3,225,910.96-2,861,064.98-2,624,224.73-345,588.51
其他收益3,207,567.352,181,061.25736,999.53,807,681.83
营业利润平衡项目0000
四、营业利润47,511,195.845,830,973.1519,947,417.7649,224,854.95
加:营业外收入24,907,127.9924,724,652.333,110.83173,394.71
减:营业外支出707,904.87223,394.541,068.011,487,395.08
利润总额平衡项目0000
五、利润总额71,710,418.9270,332,230.9419,949,460.5847,910,854.58
减:所得税费用3,900,391.763,552,464.262,424,151.655,433,268.98
六、净利润67,810,027.1666,779,766.6817,525,308.9342,477,585.6
持续经营净利润67,810,027.1666,779,766.6817,525,308.9342,477,585.6
归属于母公司股东的净利润61,157,474.4259,967,581.4815,355,110.2841,979,286.76
少数股东损益6,652,552.746,812,185.22,170,198.65498,298.84
(一)基本每股收益0.50.550.140.39
(二)稀释每股收益0.50.550.140.39
八、其他综合收益-3,433,573.73-3,324,650.96-1,525,944.83-1,984,158.55
归属于母公司股东的其他综合收益-3,104,980.72-3,006,481.86-1,525,253.19-1,704,387.12
九、综合收益总额64,376,453.4363,455,115.7215,999,364.140,493,427.05
归属于母公司股东的综合收益总额58,052,493.756,961,099.6213,829,857.0940,274,899.64
归属于少数股东的综合收益总额6,323,959.736,494,016.12,169,507.01218,527.41
公告日期2023-10-212023-07-312023-04-252023-04-25
审计意见(境内)标准无保留意见标准无保留意见
TOP↑